United Therapeutics announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational external liver assist device, miroliverELAP, on April 8, 2026. The device, developed by Miromatrix Medical Inc., a wholly‑owned subsidiary of United Therapeutics, is designed to support patients with acute liver failure by providing external blood‑circulation support while the native liver recovers or until a transplant becomes available.
The RMAT designation is a regulatory milestone that signals the FDA’s recognition of miroliverELAP’s potential to address a serious unmet medical need. It provides the company with priority review, the possibility of accelerated approval pathways, and access to certain incentives that can shorten the time to market. These benefits are intended to speed the development of regenerative therapies for life‑threatening conditions.
By receiving RMAT status, United Therapeutics expands its product portfolio beyond its established pulmonary arterial hypertension franchise. The acute liver failure market is projected to grow from an estimated US$1.8 billion in 2025 to US$3.0 billion by 2032, a CAGR of 7.8 %. The device’s early‑stage development, coupled with the market’s size and the lack of effective non‑transplant therapies, positions miroliverELAP as a potential new revenue stream and a long‑term growth driver for the company.
United Therapeutics reported positive results from a Phase 1 study of miroliverELAP in January 2026, in which five patients with acute liver failure who were not candidates for transplant survived the treatment period and experienced no device‑related serious adverse events. Full study results are expected to be published in the second half of 2026, and the company plans to pursue further clinical development to support eventual regulatory approval.
Jeff Ross, president of Miromatrix, said the designation “highlights the critical unmet need we are addressing and the promising potential of miroliverELAP as a novel therapeutic option.” The announcement underscores United Therapeutics’ broader strategy of advancing regenerative medicine and organ‑manufacturing technologies, complementing its core pulmonary arterial hypertension products and positioning the company for future innovation in organ support therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.